Tislelizumab plus platinum and etoposide versus placebo plus platinum and etoposide as first-line treatment for extensive-stage small-cell lung cancer: patient-reported outcomes in the RATIONALE-312 trial

Key Points

• To evaluate the impact of tislelizumab plus chemotherapy on patient-reported outcomes in extensive-stage small-cell lung cancer.
• Conducted the RATIONALE-312 trial comparing tislelizumab plus chemotherapy to placebo plus chemotherapy.
• Measured health-related quality of life (HRQoL) and patient-reported symptoms.
• Assessed the efficacy and safety of the combination treatment.
• Tislelizumab plus chemotherapy maintained or improved HRQoL compared to placebo plus chemotherapy.
• The combination showed positive patient-reported symptom outcomes.
• Findings support tislelizumab as a viable first-line treatment for advanced ES-SCLC.